The Feasibility Of Simultaneous Transurethral Resection Of Bladder Cancer And Prostate:a Meta-analysis

Objective:To evaluate the efficacy and safety of transurethral resection of bladder cancer(BC)combined with benign prostatic hyperplasia(BPH).Methods:We searched the database of Wanfang,PubMed,CNKI,EMBASE,MEDLINE,CBM,Wep,and The Cochrane Library.Systematic search all clinically relevant randomized controlled trials(RCT)and non-randomized controlled studies(NRCT)deadline to March 2018 which comparing TURBT + TURP and TURBT alone with non-invasive bladder cancer(NMIBC)combined with benign prostatic hyperplasia(BPH).Development of related inclusion and exclusion criteria for the detection of literature,analysis using related software(Review Manage 5.3),Describe the results with OR,95%CI,and bias,heterogeneity,sensitivity and description analysis of relevant results,and using the Cochrane Collaboration bias for risk assessment for the RCT studies and use the Newcastle-Ottawa Scale(NOS)for the NRCT studies.Results:Twenty studies including 17.nonrandomized controlled trials(NRC、Ts)and 3 randomized controlled trials(RCTs)involved 2177 patients were included in this study.The results showed that the tumor recurrence rate was significantly different between the same group and the control group[OR=0.77,95%CI(0.63,0.93),P=0.007];there was no significant difference in the recurrence rate of prostatic fossa tumors and urethra[OR=1.02,95%CI(0.70,1.49),P=0.91];and have no significant difference in the incidence of complications[OR=0.65,95%CI(0.41,1.04),P=0.07].Conclusion:The combination of TURBT and TURP in NMIBC patients with BPH does not increase the risk of tumor recurrence,ectopic implantation,and the incidence of surgical complications,It is a safe and feasible method.